Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项在健康受试者中进行的关于盐酸克林霉素胶囊的单剂量、随机、开放性、交叉的生物等效性研究
[Translation] A single-dose, randomized, open-label, crossover bioequivalence study of clindamycin hydrochloride capsules in healthy subjects
在健康男性和女性受试者中于空腹/餐后情况下评价盐酸克林霉素胶囊和Cleocin HCl®的吸收速度和吸收程度,评价两制剂间是否具有生物等效性。评估受试制剂盐酸克林霉素胶囊和Cleocin HCl®在中国健康受试者中的安全性。
[Translation] To evaluate the absorption rate and extent of Clindamycin Hydrochloride Capsules and Cleocin HCl® in healthy male and female subjects under fasting/fed conditions and to evaluate whether the two preparations are bioequivalent. To assess the safety of the test preparations Clindamycin Hydrochloride Capsules and Cleocin HCl® in healthy Chinese subjects.
100 Clinical Results associated with Qionglai Tianyin Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Qionglai Tianyin Pharmaceutical Co., Ltd.
100 Deals associated with Qionglai Tianyin Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Qionglai Tianyin Pharmaceutical Co., Ltd.